Welcome to the official InxMed website

OUR SCIENCE

Priming tumor microenvironment with regimen,killing cancer cells and consolidating treatment via specified therapy

R&D PIPELINE

Pipeline

Time of issue:2022-04-18 10:27:14
Asset Modality / Target Regimen Indication Discovery Pre-Clinical FIH POC Pivotal Status
IN10018 Small molecular FAK inhibitor + PLD

Platinum Resistant Ovarian Cancer

 
Pivotal study initiated in 2022
+ MEKi

RAS-mu Tumor

 
PoC to be completed in 2022
Regimen undisclosed

PROC, TNBC, HNSCC and Other PLD Indicated Cancers

 
PoC expected in 2023
+ KRASG12C inhibitor

KRAS G12C-mu Solid Tumor

 
PoC expected in 2023

+ IO bispecific

PDAC

 
CTP approved Q3 2022
3rd EGFR TKI

EGFR-mu NSCLC

 
PoC to be initiated in 2022
IN30705 ADC Targeting FAP Mono / Combo Solid Tumor
 
CTP expected Q4 2022
INES103 Antibody Target undisclosed Combo Solid Tumor
 
CTP expected Q4 2022
IN30718 ADC Target undisclosed Mono Solid Tumor
 
PCC nominated in 2023
IN20019 Small molecular Target undisclosed Mono Solid Tumor
 
PCC nominated in 2023

LATEST NEWS

InxMed
2022-09-08

InxMed Announces First Patient Dosed in Pivotal Phase 2 Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

NANJING, China, Sep 8th, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study evaluating IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC).
白箭头
InxMed
2022-05-30

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Platinum-Resistant Recurrent Ovarian Cancer at ASCO 2022

NANJING, China, May 30, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC), will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) from June 3, 2022 to June 7, 2022. Abstract was published on the ASCO's website(Abstract #:5567). The data showed that patients receiving combination of IN10018 with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%(Poster #:445).
白箭头
BioWorld:Inxmed
2022-03-17

BioWorld:Inxmed raises $50M to develop cancer therapy in the US, China

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.
白箭头
Dialogue
2018-08-13

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.
白箭头
Freehand
2019-07-29

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"
白箭头
 InxMed

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO